CEACAM5 and neoplasm: After completing three cycles of combination therapy, the patient discontinued treatment, but sustaining benefits continued to be observed for several months, with a significant tail effect: tumor size reduction, reversal of lymph node enlargement, substantial improvement in clinical symptoms, and a decrease in serum CEA levels.